Joinn Laboratories (06127) will provide Staidson Group with comprehensive pharmaceutical R&D services covering non-clinical and clinical trial stages.

Joinn Laboratories (06127) announced that on December 20, 2024, the company entered into a 2025 Staidson Research and Development Service Framework Agreement with Staidson, with a term from January 1, 2025 to December 31, 2025. The company is required to provide comprehensive pharmaceutical research and development services covering both non-clinical and clinical trial stages to the Staidson Group in accordance with the 2025 Staidson Research and Development Service Framework Agreement. As a result of our long-term collaboration with the Staidson Group, we are able to further expand into the pharmaceutical contract research organization service market and enhance our brand reputation. The directors believe that the 2025 Staidson Research and Development Service Framework Agreement aligns with the company's business and commercial objectives.